Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $18 | $21 | $25 | $21 |
| G&A Expenses | $7 | $7 | $7 | $6 |
| SG&A Expenses | $7 | $7 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $29 | $32 | $27 |
| Operating Income | -$25 | -$29 | -$32 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $3 | $3 | $4 |
| Pre-Tax Income | -$20 | -$25 | -$29 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20 | -$25 | -$29 | -$23 |
| % Margin | – | – | – | – |
| EPS | -0.32 | -0.49 | -0.57 | -0.46 |
| % Growth | 34.7% | 14% | -23.9% | – |
| EPS Diluted | -0.32 | -0.49 | -0.57 | -0.46 |
| Weighted Avg Shares Out | 62 | 52 | 50 | 50 |
| Weighted Avg Shares Out Dil | 62 | 52 | 50 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $3 | $3 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$20 | -$29 | -$32 | -$27 |
| % Margin | – | – | – | – |